Gemfibrozil Reduces Plasma C-Reactive Protein Levels in Abdominally Obese Men With the Atherogenic Dyslipidemia of the Metabolic Syndrome

This publication has 13 references indexed in Scilit:

• Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2002
• Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial
  The American Journal of Medicine, 2002
• Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men
  International Journal of Obesity, 2001
• Effect of Statin Therapy on C-Reactive Protein Levels
  JAMA, 2001
• Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events
  JAMA, 2001
• Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
  New England Journal of Medicine, 1999
• Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
  Nature, 1998
• Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease.
  Heart, 1997
• C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study
  BMJ, 1996
• Mechanism of action of gemfibrozil on lipoprotein metabolism.
  Journal of Clinical Investigation, 1985